Faeth Therapeutics will present PK/PD modeling for its oral PI3K/AKT/mTOR inhibitor combination PIKTOR at STOP Cancer on Aug. 8.
The analysis supported dose selection for the ongoing Phase 2 FTH-PIK-201 trial in second-line advanced endometrial cancer.
The work points to a recommended Phase 2 regimen intended to balance pathway inhibition with tolerability, without reporting clinical efficacy outcomes.
FTH•
